Core Insights - Roivant Sciences Ltd. is recognized for its innovative drug development approach, utilizing technology and data to create new medicines through its unique subsidiary model known as "Vants" [1] Group 1: Stock Performance - Cowen & Co. has reiterated a "Buy" rating for Roivant Sciences, indicating strong confidence in the company's growth potential within the healthcare sector [2][5] - Roivant's stock is currently trading at $28.89, reflecting a price increase of approximately 3.73% or $1.04 [3][5] - Over the past year, Roivant's stock has experienced significant volatility, with a high of $29.71 and a low of $8.73, showcasing both risk and reward potential for investors [4] Group 2: Market Metrics - The company's market capitalization is approximately $20.68 billion, with a trading volume of about 4.25 million shares, indicating strong investor interest [4][5] - The stock has shown fluctuations today, with a low of $28.44 and a high of $29.64, reflecting its dynamic nature in the market [3]

Summary of Roivant Sciences Conference Call Company and Industry Overview - **Company**: Roivant Sciences (NasdaqGS:ROIV) - **Industry**: Biotechnology, specifically focusing on lipid nanoparticles and mRNA vaccine technology Key Points and Arguments 1. **Settlement Announcement**: Roivant announced a global settlement of $2.25 billion with Moderna, resolving patent litigation related to the COVID-19 vaccine [5][6][10] 2. **Payment Structure**: The settlement includes a $950 million upfront payment to be made in July 2026, and a contingent payment of $1.3 billion based on the outcome of a legal appeal regarding Section 1498 [5][6][11] 3. **Market Share Impact**: The settlement covers Moderna's global market share of COVID vaccines, which is approximately one-third of the total market [6][13] 4. **Historical Context**: This settlement is noted as one of the largest outcomes in patent litigation history, with the potential to be the largest paid-out case among those that would have gone to jury [9][10] 5. **Use of Settlement Proceeds**: Roivant plans to invest the settlement proceeds into its current pipeline and upcoming launches, while also expanding its share buyback program to $1 billion [11][12] 6. **Appeal Process**: The appeal regarding Section 1498 is expected to take 18 to 36 months, with Roivant expressing confidence based on previous favorable rulings [13][24] 7. **Pfizer Litigation**: The company is pursuing a similar case against Pfizer-BioNTech, with the expectation that the outcome of the Moderna case may influence negotiations with Pfizer [31][65] 8. **Brepocitinib Update**: Roivant announced that the NDA for brepocitinib was accepted by the FDA with priority review, with a potential launch by the end of September 2026 [15][57] 9. **Capital Allocation Strategy**: Roivant aims to be efficient in capital allocation, balancing share buybacks with investments in new opportunities and existing programs [70][82] Additional Important Information 1. **Legal Precedents**: The settlement with Moderna sets a legal precedent that may impact the ongoing litigation with Pfizer, although Pfizer is not precluded from making its own validity challenges [76] 2. **Future Royalties**: The settlement is structured as a lump sum that covers all future royalties, eliminating the need for additional payments [51] 3. **Market Preparation for Brepocitinib**: Roivant is actively preparing for the launch of brepocitinib, including building a field force for medical engagement and patient education [78][57] 4. **Investor Relations**: Roivant encourages investors to review SEC filings for more information on forward-looking statements and associated risks [2] This summary encapsulates the critical aspects of Roivant Sciences' recent conference call, highlighting the significant settlement with Moderna, ongoing litigation with Pfizer, and strategic plans for future growth and capital allocation.

Core Viewpoint - Roivant's subsidiary Genevant Sciences and Arbutus Biopharma have reached a $2.25 billion global settlement with Moderna to resolve patent infringement claims related to the use of Genevant's and Arbutus' lipid nanoparticle (LNP) delivery technology in COVID-19 vaccines [1][2][4]. Financial Summary - Moderna will pay $950 million upfront in July 2026 and an additional $1.3 billion contingent on a favorable appellate ruling regarding the applicability of Section 1498 to Genevant's and Arbutus' claims [2][4]. - If the contingent payment is realized, this settlement will be the largest disclosed patent settlement in the pharmaceutical industry and the second largest across any industry [4]. Legal and Patent Implications - The settlement includes a judgment of infringement and no invalidity on four Genevant/Arbutus patents, holding Moderna accountable for its unauthorized use of the technology [4]. - Genevant will grant Moderna a global non-exclusive license to its LNP delivery technology for infectious disease applications and a covenant not to sue for certain patents and products [2][4]. Company Statements - Genevant's CEO expressed satisfaction with the settlement, emphasizing the importance of their LNP technology in addressing the COVID-19 pandemic [3]. - Arbutus' CEO highlighted the transformative nature of the settlement and the recognition of their scientists' contributions to drug development [3]. Ongoing Litigation - Genevant continues its litigation against Pfizer/BioNTech, whose Comirnaty sales account for approximately two-thirds of global COVID-19 vaccine sales [4]. Shareholder Actions - Roivant's board has approved a $1 billion share repurchase program, which includes a previously authorized $500 million [4][5].

Core Viewpoint - Genevant Sciences and Arbutus Biopharma have reached a $2.25 billion global settlement with Moderna to resolve patent infringement claims related to the unauthorized use of their lipid nanoparticle (LNP) delivery technology in COVID-19 vaccines [1][2]. Settlement Details - Moderna will pay $950 million upfront in July 2026 and an additional $1.3 billion contingent on a favorable appellate ruling regarding the applicability of Section 1498 to Genevant's and Arbutus' claims [2][4]. - The settlement includes a judgment of infringement and no invalidity on four patents held by Genevant and Arbutus [4]. - Genevant will grant Moderna a global non-exclusive license to its LNP delivery technology for infectious disease applications and a covenant not to sue for certain patents and products [2][4]. Company Statements - Genevant's CEO expressed satisfaction with the settlement, emphasizing the importance of their technology in addressing the pandemic [3]. - Arbutus' CEO highlighted the recognition of their scientists' contributions to drug development and the significance of the settlement for the company [3]. Financial Implications - If the contingent payment is realized, this settlement will be the largest disclosed patent settlement in the pharmaceutical industry and the second largest across all industries [4]. - Arbutus is evaluating a potential return of capital to shareholders in conjunction with the upfront payment [4]. Ongoing Litigation - The litigation against Pfizer/BioNTech regarding the use of Arbutus' patented LNP technology in their COVID-19 vaccines is still ongoing [4].

Core Viewpoint - Roivant's subsidiary Genevant Sciences and Arbutus Biopharma have reached a $2.25 billion global settlement with Moderna to resolve patent infringement claims related to the use of Genevant's and Arbutus' lipid nanoparticle (LNP) delivery technology in COVID-19 vaccines [1][2][4] Financial Summary - Moderna will pay $950 million upfront in July 2026 and an additional $1.3 billion contingent on a favorable appellate ruling regarding patent infringement claims [2][4] - If the contingent payment is realized, this settlement will be the largest disclosed patent settlement in the pharmaceutical industry and the second largest in any industry [4] Legal and Licensing Details - The settlement includes a judgment of infringement and no invalidity on four Genevant/Arbutus patents [4] - Genevant will grant Moderna a global non-exclusive license to its LNP delivery technology for infectious disease applications, ending all patent-infringement litigation against Moderna related to its COVID-19 vaccines [2][4] Company Statements - Genevant's CEO expressed satisfaction with the settlement, emphasizing the importance of their LNP technology in addressing the COVID-19 pandemic [3] - Arbutus' CEO highlighted the recognition of their scientists' contributions to drug development through the invention of LNP delivery technology [3] Ongoing Litigation - Genevant continues litigation against Pfizer/BioNTech, whose Comirnaty sales account for approximately two-thirds of global COVID-19 mRNA vaccine sales [4]

PresentationYaron WerberTD Cowen, Research Division All right. Well, good morning, everybody, and thank you once again for joining us for the 46th Annual TD Cowen Healthcare Conference. I'm Yaron Werber from the biotech team, and it's a great pleasure to moderate the next fireside chat with Roivant with the CEO, really needs no introduction, Matt Gline. Good to see you. Really appreciate you being here. ...

Summary of Roivant Sciences FY Conference Call (March 03, 2026) Company Overview - **Company**: Roivant Sciences (NasdaqGS:ROIV) - **Event**: 46th Annual TD Cowen Healthcare Conference Key Points PDUFA Date and Drug Launch - The PDUFA date for Roivant's therapy is set for the third quarter of 2026, with a planned launch by the end of September 2026 [6][8] - The company received a priority review from the FDA, indicating confidence in the therapy's data quality [10] Market Expectations and Physician Feedback - Surveys indicate that physicians expect a 30% market share for the new therapy, which aligns with historical accuracy of such surveys [12][13] - There is significant excitement among physicians regarding the potential to reduce steroid burden for patients [16] Treatment Landscape - Approximately 75% of the 40,000 patients tracked are currently managed with DMARDs and oral steroids, while 25% are on IVIG or off-label treatments [17][18] - The new therapy is expected to attract patients dissatisfied with current treatments, particularly those with high steroid burdens [19][20] Efficacy and Labeling - The therapy is anticipated to have a broad indication for dermatomyositis, aiming to serve a wide patient population [13][14] - The study included a steroid taper, and the company plans to provide extensive information on managing steroid reduction [15] Clinical Trials and Data - The NEPTUNE study showed a 29% relapse rate at the 45 mg dose, significantly better than Humira's 62% [23] - The CLARITY studies are designed to mirror NEPTUNE, with a focus on steroid tapering [24][26] Future Studies and Approvals - The company is preparing for phase 3 studies based on positive phase 2 data, with discussions ongoing with the FDA regarding trial design [48][49] - The goal is to maintain consistency with successful phase 2 data in future studies [49] Mosliciguat and Other Programs - Mosliciguat is being studied for pulmonary hypertension with promising phase 1 data showing significant peripheral vascular resistance reduction [61] - The phase 2b PHOCUS study is expected to read out data in the second half of the year, focusing on PVR and six-minute walk metrics [62][64] IMVT-1402 for Graves' Disease - Data from the FORWARD studies for Graves' disease is expected next year, with a focus on controlling refractory patients [82][83] - The therapy aims to provide a new treatment option for patients who are currently uncontrolled on antithyroid drugs (ATDs) [82][84] Legal Matters - Ongoing litigation with Moderna regarding intellectual property, with the company feeling confident about its position [92][93] Additional Insights - The company is focused on addressing the needs of patients who are currently dissatisfied with existing therapies, particularly in underdeveloped treatment landscapes [20][73] - There is a strong emphasis on the importance of patient comfort and the potential for new therapies to improve quality of life [70][72]

Core Insights - Priovant Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for brepocitinib for treating dermatomyositis and granted it Priority Review status, with a target action date set for Q3 2026 and a potential launch at the end of September 2026 [1][6] Group 1: FDA Review and Study Results - The Priority Review designation was based on the significant unmet medical need in dermatomyositis and positive results from the Phase 3 VALOR study, which was the longest and largest interventional trial in this area [2][6] - The VALOR study enrolled 241 subjects and demonstrated that brepocitinib 30 mg resulted in statistically significant improvements in the myositis Total Improvement Score (TIS) at Week 52 compared to placebo, with benefits observed as early as Week 4 [4][6] - More than two-thirds of patients on brepocitinib 30 mg achieved a TIS40, which is twice the minimum clinically important difference, while over half also maintained a steroid dependency of ≤2.5 mg/day [4][6] Group 2: Patient Impact and Company Commitment - The medical community has expressed excitement over the potential for brepocitinib to be the first targeted therapy approved for dermatomyositis, addressing a long-standing need for innovative treatments [3][4] - The CEO of Priovant emphasized the company's commitment to working closely with the FDA to expedite the availability of brepocitinib for patients [4][8] Group 3: Safety and Broader Development - The safety profile of brepocitinib appears similar to that of approved JAK and TYK2 inhibitors, with serious infections noted in the 30 mg group but manageable with medical intervention [5][7] - Priovant is also developing brepocitinib for other conditions, including non-infectious uveitis and cutaneous sarcoidosis, indicating a broader therapeutic potential for this compound [8]

Group 1 - Roivant Sciences Ltd. (NASDAQ:ROIV) is considered a promising low-cost stock, with multiple firms raising their price targets following positive Phase 2 data for brepocitinib in cutaneous sarcoidosis [1][2][3] - Citi raised its price target for Roivant Sciences to $35 from $26 while maintaining a Buy rating, citing the drug's growth potential and integrating revenue projections into its financial model [1][4] - H.C. Wainwright also increased its price target to $33 from $26, characterizing the Phase 2 data as impressive and adding this indication to its valuation model [2] - Bank of America raised its price target to $26 from $22 with a Neutral rating, noting that the FQ3 2026 results were in line and highlighting the positive Phase 2 topline results of brepocitinib [3]

Market Overview - Richard Bernstein, CEO of Richard Bernstein Advisors, discussed the equity markets on CNBC, noting a significant broadening of the market since late October 2025 [1] - The unexpected strength of the overall economy has contributed to this shift, with nominal GDP exceeding 8% last quarter, a level not seen since 2006, excluding the post-pandemic period [2] Investment Strategy - Bernstein emphasized a macro-focused investment strategy, avoiding individual stock picks, and questioned the rationale behind paying high valuations for well-known tech stocks when similar growth can be found at lower valuations globally [3] Promising Low-Cost Stocks - A list of 11 promising low-cost stocks was compiled, focusing on those priced between $10 and $30 and favored by elite hedge funds [6] - The strategy of imitating top hedge fund stock picks has historically outperformed the market, with a reported return of 427.7% since May 2014 [7] Company Highlights Roivant Sciences Ltd. (NASDAQ:ROIV) - Roivant Sciences is highlighted as a promising low-cost stock, with a price target raised by Citi to $35 from $26 due to positive Phase 2 data for brepocitinib [8][9] - H.C. Wainwright also increased its price target for Roivant to $33, citing impressive Phase 2 data [9] - Bank of America raised its price target to $26 from $22, noting that FQ3 2026 results were in line with expectations [10] News Corporation (NASDAQ:NWSA) - News Corporation is also listed as a promising low-cost stock, with a recent price target adjustment by Citi to $39 from $40 while maintaining a Buy rating [12] - The company reported a 6% revenue increase to $2.4 billion and a 9% expansion in total segment EBITDA to $521 million for FQ2 2026 [13] - Despite a 21% decline in net income from continuing operations, adjusted EPS rose to $0.40, and profitability margins improved to 22.1% [13] - Performance was driven by the Dow Jones and Digital Real Estate segments, while the News Media segment faced challenges [14]